Zevra Therapeutics Inc (ZVRA)

Apr 03, 2025

Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha

Apr 03, 2025

Mar 31, 2025

Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com India

Mar 31, 2025

Mar 31, 2025

Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener

Mar 31, 2025

Mar 31, 2025

Zevra Therapeutics Files Preliminary Proxy - The Manila Times

Mar 31, 2025

Mar 31, 2025

Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan

Mar 31, 2025

Mar 26, 2025

Trend Tracker for (ZVRA) - news.stocktradersdaily.com

Mar 26, 2025

Mar 23, 2025

John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st

Mar 23, 2025

Mar 23, 2025

Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance

Mar 23, 2025

Mar 22, 2025

Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus

Mar 22, 2025

Mar 22, 2025

Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada

Mar 22, 2025

Mar 21, 2025

Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com

Mar 21, 2025

Mar 21, 2025

ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView

Mar 21, 2025

Mar 18, 2025

Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com

Mar 18, 2025

Mar 17, 2025

Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia

Mar 17, 2025

Mar 17, 2025

Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 17, 2025

HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World

Mar 17, 2025

Mar 16, 2025

(ZVRA) On The My Stocks Page - news.stocktradersdaily.com

Mar 16, 2025

Mar 15, 2025

Guggenheim Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World

Mar 15, 2025

Mar 14, 2025

Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 14, 2025

Mar 14, 2025

Roth Capital Predicts Weaker Earnings for Zevra Therapeutics - Defense World

Mar 14, 2025

Mar 14, 2025

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 14, 2025

Mar 13, 2025

Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Mar 13, 2025

Mar 13, 2025

Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves - TipRanks

Mar 13, 2025

Mar 13, 2025

Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India

Mar 13, 2025

Mar 13, 2025

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks

Mar 12, 2025

Mar 12, 2025

Sector Update: Health Care -March 12, 2025 at 01:43 pm EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 12, 2025

Mar 12, 2025

Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World

Mar 12, 2025

Mar 12, 2025

Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics: Q4 Earnings Snapshot - The Washington Post

Mar 12, 2025

Mar 12, 2025

Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks

Mar 12, 2025

Mar 11, 2025

ZEVRA THERAPEUTICS Earnings Results: $ZVRA Reports Quarterly Earnings - Nasdaq

Mar 11, 2025

Mar 11, 2025

Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses - Investing.com

Mar 11, 2025

Mar 11, 2025

Zevra Therapeutics earnings missed by $0.27, revenue topped estimates - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025

Mar 11, 2025

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewswire

Mar 11, 2025

Mar 11, 2025

Zevra Earnings: Q4 Revenue Surges to $12M as MIPLYFFA Launch Gains Traction - StockTitan

Mar 11, 2025